Company: CERO
Filing Date: 2025-07-21
Form Type: S-1
Source: 0001213900-25-066152
Chunk: 260

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-21
Form: S-1
Chunk 260
---
 broker-dealer. The foregoing should 
 not be construed in and of itself as an admission by Mr. Zaino as to beneficial ownership of the securities beneficially owned directly 
 by Keystone and indirectly by Ranz Group, LLC.                                                                                          |

148 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS Other than the compensation agreements and other arrangements described under the sections entitled “ Executive Compensation” and “ Director Compensation” above and the transactions described below, since January 1, 2023, there has not been and there is not currently proposed, any transaction or series of similar transactions to which we were, or will be, a party in which:

| ● | the amount involved exceeded, or will exceed, $120,000 (or,                               
 if less, 1% of the average of our total asset amounts at December 31, 2023 and 2024); and |

| ● | any director, executive officer, holder of 5% or more of                                                                                 
 any class of our capital stock or any member of the immediate family of, or entities affiliated with, any of the foregoing persons, had, 
 or will have, a direct or indirect material interest.                                                                                    |

CERo Relationships and Related Party Transactions Collaboration and Option Agreement On March 3, 2020, Legacy CERo entered into a collaboration and option agreement (“Collaboration Agreement”) with a collaborative partner that was an investor of Legacy CERo, pursuant to which each party was granted a royalty-free, nonexclusive, worldwide license to share the other party’s technologies to create bi-functional T-cells. Legacy CERo was responsible for all employee and other internal costs incurred in the performance of all of Legacy CERo’s R&D activities, with approved cost overruns funded by the collaborative partner. At the end of the research project, the collaborative partner would be granted the option to enter into an exclusive license for the further development of the combined drug. Under the Collaboration Agreement, the collaborative partner paid us $0 for the year ended December 31, 2023. The Collaboration Agreement terminated on March 3, 2023. PIPE Financings In February 2024, we issued and sold an aggregate of 10,089 shares of Series A Preferred Stock, 306 Series A Warrants and 2,500 Preferred Warrants, at a price of $1,000 per share of Series A Preferred Stock, for aggregate cash proceeds of approximately $8.0 million, plus additional cash proceeds of up to